Further experimental validation in an independent CRC cohort showed that 67% (67 of 101) of cases showed more than 1.5-fold upregulation of DLGAP1-AS2 in CRCs compared with the adjacent NCTs (Fig. 1 C). The gene discussed is DLGAP1; the disease is colorectal carcinoma.